Free Trial
NASDAQ:ENLV

Enlivex Therapeutics Q1 2023 Earnings Report

Enlivex Therapeutics logo
$1.05 -0.05 (-4.55%)
Closing price 05/7/2025 03:58 PM Eastern
Extended Trading
$1.05 0.00 (0.00%)
As of 05/7/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.40
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Enlivex Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enlivex Therapeutics Announcement Details

Quarter
Q1 2023
Time
Q1 2023 Earnings Release
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Enlivex Therapeutics' Q4 2024 earnings is scheduled for Friday, June 13, 2025

Earnings Documents

Enlivex Therapeutics Earnings Headlines

Am I wrong for thinking this about you?
The media says Trump supporters are giving up. But I know the truth: you’re the kind of American who doesn’t flinch when the going gets tough. And now there’s a legal, tax-free IRS strategy created under President Trump that could protect your retirement savings from Bidenflation and beyond.
See More Enlivex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email.

About Enlivex Therapeutics

Enlivex Therapeutics (NASDAQ:ENLV), together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

View Enlivex Therapeutics Profile

More Earnings Resources from MarketBeat